The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na?ve Metastatic Castration-resistant Prostate Cancer.
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na?ve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683.